MedPath

Shanghai Yingli Pharmaceutical Co., Ltd

Shanghai Yingli Pharmaceutical Co., Ltd logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

25

Active:1
Completed:1

Trial Phases

3 Phases

Phase 1:18
Phase 2:5
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (75.0%)
Phase 2
5 (20.8%)
Phase 4
1 (4.2%)

A Study of AK-1286 in Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2025-01-16
Last Posted Date
2025-01-16
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Target Recruit Count
50
Registration Number
NCT06779045

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Phase 1
Not yet recruiting
Conditions
Metastatic Pancreatic Cancer
Interventions
First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Target Recruit Count
120
Registration Number
NCT06662669

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Phase 2
Not yet recruiting
Conditions
Peripheral T Cell Lymphoma
Interventions
First Posted Date
2024-08-12
Last Posted Date
2024-08-12
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Target Recruit Count
606
Registration Number
NCT06548347

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Phase 4
Not yet recruiting
Conditions
Indolent B-cell Lymphoma
Interventions
First Posted Date
2024-04-03
Last Posted Date
2024-04-03
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Target Recruit Count
88
Registration Number
NCT06343935

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2023-10-24
Last Posted Date
2025-04-09
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Target Recruit Count
60
Registration Number
NCT06096974
Locations
🇺🇸

The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Huntsman Cancer Institute and Hospital, University of Utah, Salt Lake City, Utah, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.